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Abstract
Background: Very recently, a sub-analysis of genome-wide association scans revealed that the non-coding single nucleotide
polymorphism (SNP) rs12212067 in the FOXO3A gene is associated with a milder course of Crohn’s disease (CD) (Cell
2013;155:57–69). The aim of our study was to evaluate the clinical value of the SNP rs12212067 in predicting the severity of
CD by correlating CD patient genotype status with the most relevant complications of CD such as stenoses, fistulas, and CD-
related surgery.
Methodology/Principal Findings: We genotyped 550 CD patients for rs12212067 (FOXO3A) and the three common CD-
associated NOD2 mutations rs2066844, rs2066847, and rs2066847 and performed genotype-phenotype analyses.
Results: No significant phenotypic differences were found between the wild-type genotype TT of the FOXO3A SNP
rs12212067 and the minor genotypes TG and GG independently from NOD2 variants. The allele frequency of the minor G
allele was 12.7%. Age at diagnosis, disease duration, body mass index, surgery rate, stenoses, fistula, need for
immunosuppressive therapy, and disease course were not significantly different. In contrast, the NOD2 mutant
p.Leu1007fsX1008 (rs2066847) was highly associated with penetrating CD (p = 0.01), the development of fistulas
(p = 0.01) and stenoses (p = 0.01), and ileal disease localization (p = 0.03). Importantly, the NOD2 SNP rs2066847 was a strong
separator between an aggressive and a mild course of CD (p = 2.9961025), while the FOXO3A SNP rs12212067 did not
separate between mild and aggressive CD behavior in our cohort (p = 0.35). 96.2% of the homozygous NOD2
p.Leu1007fsX1008 carriers had an aggressive disease behavior compared to 69.3% of the patients with the NOD2 wild-
type genotype (p = 0.007).
Conclusion/Significance: In clinical practice, the NOD2 variant p.Leu1007fsX1008 (rs2066847), in particular in homozygous
form, is a much stronger marker for a severe clinical phenotype than the FOXO3A rs12212067 SNP for a mild disease course
on an individual patient level despite its important impact on the inflammatory response of monocytes.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the two
main forms of inflammatory bowel disease (IBD) characterized by
a chronic relapsing disease course based on a chronic inflamma-
tion of the intestine, frequently resulting in a stricturing and
penetrating disease phenotype in CD patients. Since the
introduction of biological therapies in the treatment of IBD,
therapeutic options have dramatically improved [1]. Anti-TNF
therapies have been proven in various clinical trials to alleviate the
IBD disease course by rapidly inducing and maintaining clinical
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remission and mucosal healing in IBD patients [1]. These
therapies are indispensable for the management of moderate to
severe forms of IBD. Several novel compounds and ‘‘biosimilars’’
are currently undergoing clinical trials and will further increase the
treatment options in IBD [1].
Therefore, it is necessary to personalize treatment algorithms
according to the individual risk profile. A major task in daily
clinical practice thus is the selection of the appropriate therapy for
each CD patient [2]. For example, some CD patients will benefit
from early initiation of biological therapies. The early prediction of
the disease course after initial diagnosis therefore becomes
increasingly important for subsequent therapeutic decisions.
Several clinical, serological, and genetic factors have been
investigated for disease prediction.
Likely the most relevant genetic factors associated with a
complicated course of CD are the three common mutations of the
NOD2 protein, p.Arg702Trp (rs2066844), p.Gly908Arg
(rs2066847), and p.Leu1007fsX1008 (rs2066847), which have
been associated with a complicated disease course of CD and in
particular with a stricturing and penetrating disease behaviour.
They have been described in multiply affected IBD families as a
main genetic risk factor for CD susceptibility [3,4,5,6,7,8,9]. This
phenotype is especially well-marked in the presence of the
frameshift mutation p.Leu1007fsX1008 in exon 11 of the NOD2
gene [3,4,5,6,7,8,10] which therefore has been successfully used as
a genetic marker for therapeutic decisions in CD [4,5].
Since the identification of NOD2, several genome-wide
association studies (GWAS) were performed to identify new
genetic loci for disease prediction in patients with IBD [11,12,13].
A recent meta-analysis identified and confirmed a total of 163
susceptibility loci for IBD [11], but only the NOD2 mutation status
has been translated from initial genotype-phenotype correlations
to a clinically useful genetic predictor [11,14].
Genetic differences in the IL-2 and IL-7 cytokine pathways were
also strongly correlated with disease course prognosis in CD
[15,16,17]. In particular, a noncoding SNP was identified in the
FOXO3A gene which was associated with CD prognosis although
it was not disease-associated [15]. FOXO3A encodes FOXO3, a
member of the fork-head box O family of transcription factors that
is involved in the regulation of diverse transcriptional programs
including cell-cycle control, metabolism, regulatory T cell
development, and apoptosis [18,19,20,21,22,23,24]. The minor
G allele of the FOXO3A SNP rs122112067 was associated with a
milder course of CD most likely via limitation of inflammatory
responses in monocytes through a FOXO3-driven pathway [15].
The reliable prediction of a mild disease course of CD would
represent an essential improvement in daily clinical practice by
accelerating and ensuring therapeutic decisions in patients with
IBD, especially with regard to long-term treatment. The initial
observation of an association between the minor G allele of the
FOXO3A SNP rs122112067 and a milder disease course in CD
was replicated in cohorts of the British population, but not verified
in IBD populations outside of Great Britain. Therefore, our study
represents the first attempt to replicate the association of the
FOXO3A SNP rs122112067 with a milder CD phenotype outside
the UK. In addition, it remains elusive whether this FOXO3A
SNP represents a stronger modifier of the CD course than NOD2
gene mutants, which are currently the most important genetic
markers for a severe CD phenotype.
Therefore, we first aimed to analyze a potential correlation of
the FOXO3A SNP rs122112067 genotype status with a mild
disease course in a German CD patient cohort. Our second aim
was to compare this FOXO3A SNP with the most strongly CD-
associated NOD2 mutations regarding the most important disease
outcome variables such as stenoses, fistulas, and need for surgery.
This study was aimed to clarify the clinical value of the FOXO3A




This study was approved by the local ethics committee (Medical
Faculty of the Ludwig-Maximilians-University Munich). Written,
informed consent was obtained from all patients prior to study
inclusion. Study protocols were based on the ethical principles for
medical research involving human subjects of the Helsinki
Declaration.
Study population
A total of 550 patients with CD were enrolled in this study. All
CD patients were recruited from the University Hospital Munich-
Grosshadern and from the University Hospital Munich-Innen-
stadt. Patients with indeterminate colitis were excluded. Pheno-
typic parameters were collected blinded to the results of the
genotype analyses [25] and included demographic and clinical
data (behaviour and anatomic location of IBD, disease-related
complications, surgical or immunosuppressive therapy). Two
senior gastroenterologists analyzed the data which were recorded
by patient chart analysis and a detailed questionnaire based on an
interview at the time of enrolment. The diagnosis of CD was based
on endoscopic, radiological, and histopathological parameters,
adhering to established international guidelines [26]. CD patients
were classified according to the Montreal classification [27]
including age at diagnosis (A), location (L), and behaviour (B) of
disease.
To distinguish between aggressive and mild disease, the clinical
course of CD was defined as ‘‘aggressive’’ in CD patients with a
stricturing (B2) and/or penetrating disease behaviour (B3) and/or
CD-related surgery. CD patients with a ‘‘mild’’ disease course had
a non-stricturing or non-penetrating phenotype and no CD-
related surgery (B1 according to the Montreal Classification) [27].
DNA extraction and NOD2 genotyping
Genomic DNA was isolated from peripheral blood leukocytes
by standard procedures using the DNA blood mini kit from
Qiagen (Hilden, Germany). The FOXO3A variant rs12212067
was genotyped by PCR and melting curve analysis on a
LightCycler 480 Instrument (Roche Diagnostics, Mannheim,
Germany) as previously described in detail [25,28,29]. The results
of the melting curve analyses were confirmed by DNA sequence
analysis of samples representing all three possible genotypes.
Sequences of primers and FRET probes and primer annealing
temperatures used for genotyping and for sequence analysis are
given in the supplementary data section (tables S1 and S2).
Amplification and sequence analysis of NOD2 exons 4, 8, and 11
were performed as described previously [4,28,30].
Statistical analyses
Each genetic marker was tested for Hardy-Weinberg equilib-
rium in the control population. Single-marker allelic tests were
performed with Pearson’s x2 test. All tests were two-tailed, and p-
values ,0.05 were considered significant. Odds ratios were
calculated for the minor allele at each SNP. For evaluation of
phenotypic consequences, we conducted logistic regression anal-
yses. Data and genotype-phenotype analyses were done by using
the PLINK v1.07 software (http://pngu.mgh.harvard.edu/
purcell/plink/ [31] and R-2.4.1. (http://cran.r-project.org).
FOXO3A rs12212067 and NOD2 p.Leu1007fsX1008 SNPs in Crohn’s Disease
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Results
Phenotypic characteristics of the study cohort
Table 1 shows the characteristics of the study population. A
total of 550 CD patients were included in the analysis. There was
an equal gender distribution (48.5% males), and the mean age was
41.5 years with a mean disease duration of almost 15 months. The
majority of CD patients (72.5%) was between 17 and 40 years of
age at first diagnosis of CD, and 14.4% of CD patients were
younger than 17 years at the time of CD onset. Nearly three
quarters of the patients had either stricturing or penetrating
disease behaviour (25.0% stricturing disease behaviour (B2);
49.5% penetrating disease behaviour (B3)) and more than half of
the patients (58.6%) required CD-related surgery (e.g., ileocecal
resection, fistulectomy, colectomy, or ileostomy). Over 80% of CD
patients were treated with immunosuppressive or biological
therapies (table 1). Interestingly, almost one fifth of the patients
(19.2%) had a positive family history of IBD, demonstrating a
strong role of genetic factors in this patient population.
Impact of the FOXO3A variant rs12212067 on the
phenotype of Crohn’s disease
The table S3 gives an overview over the observed minor allele
frequencies of the FOXO3A SNP rs12212067 (T.G) and the
frequencies of the three main NOD2 mutants p.Arg702Trp
(rs2066844), p.Gly908Arg (rs2066845), and p.Leu1007fsX1008
(rs2066847). Interestingly, the minor G allele frequency of the
FOXO3A SNP rs12212067 was with 12.7% identical to the allele
frequency of the frameshift mutation p.Leu1007fsX1008 in exon
11 of the NOD2 gene.
To evaluate the phenotypic consequences of the FOXO3A
variant rs12212067 in CD patients, we performed a detailed
genotype-phenotype correlation of the whole cohort of 550 CD
patients including carriers of the three main NOD2 mutants
(table 2). Four hundred and fourteen patients were homozygous
carriers of the major T allele (75.3%, FOXO3A WT), 132 patients
(24.0%) were heterozygous carriers of the minor G allele, and 4
CD patients (0.7%) were homozygous for the G allele in FOXO3A
(table 2). No significant differences were observed between the
wild-type and minor allele carriers of the FOXO3A variant
rs12212067 with respect to the age at diagnosis, disease duration,
disease behaviour, disease location, need for CD-related surgery,
and use of immunosuppressives (table 2).
Furthermore, no association with a mild disease course was
found in the four CD patients being homozygous carriers of the
FOXO3A minor allele. Three of these individuals carried none of
the three NOD2 mutations analyzed, while one CD patient was a
heterozygous carrier of the NOD2 p.Arg702Trp (rs2066844)
substitution. Two of these four patients had a stricturing or
penetrating disease behaviour (none of them was carrier of one of
the three main CD-associated NOD2 mutations analyzed); one of
these patients needed CD-related surgery (table 2). Three of these
patients had mainly ileocolonic disease; the female CD patient
(also not carrying one of the three NOD2 mutations) had isolated
colonic disease. All patients were treated with immunosuppressive
agents; three of them had anti-TNF therapy with infliximab.
Analysis regarding an aggressive versus mild Crohn’s
disease course using the genotype status of the FOXO3A
variant rs12212067 and the NOD2 variants rs2066844,
rs2066845, and rs2066847
To analyze the association between the FOXO3A SNP
rs122112067 and the subsequent disease course in our cohort of
550 CD patients, we next defined the clinical course as
‘‘aggressive’’ in patients with a stricturing (B2) and/or a fistulising
disease behaviour (B3) and/or when CD-related surgery (e.g.,
ileocecal resection, fistulectomy) became necessary. A ‘‘mild’’
clinical disease course was defined by inflammatory disease
behaviour with no complications (B1) (e.g., no need for surgery).
The majority of 403 CD patients had an aggressive disease course
(73.3%), compared to 147 patients (26.7%, table 1) with only mild
inflammatory disease.
The FOXO3A rs122112067 minor allele frequencies did not
differ significantly between the two groups (table 3; allele
frequency of 12.2% in the aggressive CD group vs. 14.3% in the
group with mild CD (p = 0.35)). Similarly, for the NOD2 variants
rs2066844 and rs2066845 no significant differences were observed
between the two groups (rs2066844: 9.7% vs. 9.9% aggressive vs.
mild; p = 0.93) (rs2066845: 4.6% vs. 3.4%; p = 0.39) regarding the
minor allele frequency (table 3).
In contrast, the NOD2 frameshift mutation p.Leu1007fsX1008
(rs2066847) in exon 11 showed significant differences in the minor
allele frequency in patients with aggressive disease compared to
those with mild disease. In individuals with aggressive CD, the
minor allele frequency of p.Leu1007fsX1008 was 15.3% versus
5.8% in patients with mild CD (p = 2.9961025; table 3).
Genotype-phenotype analysis of FOXO3A and NOD2
variants
Since the three NOD2 mutants p.Arg702Trp (rs2066844),
p.Gly908Arg (rs2066845), and p.Leu1007fsX1008 (rs2066847) are
the strongest genetic markers associated with the subsequent
disease course in CD, we performed a genotype-phenotype
correlation for the FOXO3A SNP rs12212067 in CD patients
not carrying one of the three NOD2 mutations tested (table 4).
Among the 550 CD patients, a total of 219 patients had the TT
genotype of the FOXO3A SNP (FOXO3A wild-type (WT)).
Seventy-three patients were rs12212067 minor G allele carriers
(71 heterozygous and 2 homozygous; table 4). No significant
differences were observed regarding the age at diagnosis, disease
duration, location of the disease according to the Montreal
classification, and disease behaviour in wild-type (WT) compared
to the minor G allele carriers (table 4). In both subcohorts (TT/
NOD2 WT group and TG/GG/NOD2 WT group), almost 80%
of patients were treated with immunosuppressive agents or
biological therapies (79% in the TT/NOD2 WT group vs.
78.3% in the TG/GG/NOD2 WT group). Almost every second
CD patient developed fistulas (48.0% vs. 46.1%), and 62.1% in the
TT/NOD2 WT group developed stenoses compared to 56.3% in
the TG/GG/NOD2 WT group. More than half of all CD patient
needed CD-related surgery (55.0% vs. 56.9%) (table 4).
In summary, no significant phenotypic differences were
identified between the different FOXO3A genotypes. There were
also no significant associations when both FOXO3A and NOD2
SNPs were analysed in combination. In our patient cohort, the
FOXO3A G allele was not associated with a milder CD course.
Homozygosity for the NOD2 frameshift mutation
p.Leu1007fsX1008 (rs2066847) is strongly associated with
complicated CD
Twenty-six of the 550 CD patients (4.7%) were homozygous for
the frameshift mutation p.Leu1007fsX1008 (rs2066847) in exon
11 of the NOD2 gene (table S4). These patients were nominally
younger when diagnosed with CD as compared with those
carrying none of the three tested NOD2 mutations (NOD2 wild-
type (WT); mean age of 22.4 years at diagnosis versus 28.2 years in
FOXO3A rs12212067 and NOD2 p.Leu1007fsX1008 SNPs in Crohn’s Disease
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NOD2 WT patients (23.1%), p = 0.09) (Table S4). The main
disease location was the terminal ileum in 23.1% (n = 6) of these 26
patients, compared to 32 out of 280 (11.4%) NOD2 WT patients
with a L1 disease localization (p = 0.027). Twenty-three of the
twenty-six CD patients with the homozygous p.Leu1007fs
genotype (88.5%) suffered from intestinal stenoses vs. 162/271
(59.8%) of NOD2 WT patients (p = 0.01), while 19/26 (73.1%)
had fistulas vs. 127/269 (47.2%) of NOD2 WT patients (p = 0.01).
A total of 65.4% (17/26) patients with the homozygous
p.Leu1007fs genotype needed CD-related surgery compared to
54.5% (145/266) of the NOD2 WT patients (p = 0.34) (Table S4).
In summary, 25 of the 26 CD patients carrying the
p.Leu1007fsX1008 mutation in homozygous form (96.2%) had







Mean 6 SD 41.5613.8
Range (10–80)
Disease duration (yrs)
Mean 6 SD 14.769.3
Range (0–46)
Body mass index (kg/m2)
Mean 6 SD 23.164.1
Range (13.1–40.8)
Age at diagnosis (n = 535)
#16 years (A1) 77 (14.4%)
17–40 years (A2) 388 (72.5%)
.40 years (A3) 70 (13.1%)
Location (n = 535)
Terminal ileum (L1) 79 (14.8%)
Colon (L2) 65 (12.1%)
Ileocolon (L3) 385 (72.0%)
Upper GI (L4) 6 (1.1%)
Any ileal involvement (L1+L3) 464 (86.7%)
Behaviour1 (n = 521)
Non-stricturing, non-penetrat. (B1) 133 (25.5%)
Stricturing (B2) 130 (25.0%)
Penetrating (B3) 258 (49.5%)
Clinical disease course2 (n = 550)
aggressive 403 (73.3%)
mild 147 (26.7%)
Use of immunosuppressive agents3 (n = 530) 425 (80.2%)
Surgery because of CD4 (n = 507) 297 (58.6%)
Fistulas (n = 516) 258 (50%)
Perianal fistulas (n = 516) 58 (11.2%)
Stenoses (n = 518) 329 (63.5%)
Positive family history of IBD (n = 385) 74 (19.2%)
For each variable, the number of patients included is given.
1Disease behaviour was defined according to the Montreal classification [27]. The stricturing disease phenotype was defined as the presence of stenoses without
penetrating disease. The diagnosis of stenoses was made surgically, endoscopically, or radiologically (using MR enteroclysis).
2The clinical course of CD was furthermore defined as ‘‘aggressive’’ in CD patients with a stricturing and/or penetrating disease behaviour and/or when CD-related
surgery became necessary.
3Immunosuppressive agents included azathioprine, 6-mercaptopurine, methotrexate, infliximab, and/or adalimumab.
4Only surgery related to CD-specific problems (e.g., ileocecal resection, fistulectomy, colectomy, and ileostomy) was included.
doi:10.1371/journal.pone.0108503.t001
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Table 2. Association between the FOXO3A rs12212067 genotype and CD disease characteristics based on the Montreal
classification [27].
FOXO3A (1) (2) (1) vs. (2) (1) vs. (2) (1) vs. (2)
rs12212067 TT TG/GG p-value OR 95% CI
genotype status n = 414 n = 136
Male sex (n = 550) 192 (46.4%) 75 (55.1%) 0.076 0.70 0.48–1.04
Age at diagnosis (yrs, n = 535, based on median OR+CI for . median)
Mean 6 SD 27.7612.3 25.5610.0 0.437 1.17 0.79–1.73
Range (2–70) (4–57)
Disease duration (yrs, n = 502, based on median OR+CI for . median)
Mean 6 SD 14.569.2 15.469.5 0.235 0.78 0.52–1.17
Range (0–46) (0–40)
Body mass index (n = 442, based on median OR+CI for . median)
Mean 6 SD 23.264.0 22.764.1 0.223 1.31 0.85–2.03
Range (13.1–36.6) (15.7–40.8)
Age at diagnosis (n = 403) (n = 132)
#16 years (A1) 58 (14.4%) 19 (10%) 1 0.99 0.57–1.75
17–40 years (A2) 287 (71.2%) 101 (76%) 0.237 0.76 0.48–1.20
.40 years (A3) 58 (14.4%) 12 (14%) 0.120 1.68 0.87–3.24
Location (n = 535)
(n = 401) (n = 134)
Terminal ileum (L1) 58 (14.5%) 1 (15.7%) 0.733 0.91 0.53–1.57
Colon (L2) 48 (12.0%) 17 (12.7%) 0.826 0.94 0.52–1.70
Ileocolon (L3) 289 (72.0%) 96 (71.6%) 0.924 1.02 0.66–1.58
Upper GI (L4) 6 (1.5%) 0 (0%) 0.676 1.12 0.65–1.93
Any ileal involvement 347 (86.5%) 117 (87.3%) 0.818 0.93 0.52–1.67
(L1+L3)
Behaviour1 (n = 521)
(n = 391) (n = 130)
Non-stricturing, Non-penetrat. (B1) 93 (23.8%) 41 (31.5%) 0.252 0.78 0.50–1.12
Stricturing (B2) 100 (25.6%) 29 (22.3%) 0.346 1.24 0.79–1.96
Penetrating (B3) 198 (50.6%) 60 (46.2%) 0.856 1.04 0.70–1.55
Use of immunosuppressive agents2 (n = 530)
(n = 396) (n = 134)
317 (80.0%) 108 (80.6%) 0.890 0.97 0.59–1.58
Surgery because of CD3 (n = 507)
(n = 380) (n = 127)
221 (58.2%) 76 (59.8%) 0.739 0.93 0.62–1.40
Fistulas (n = 516)
(n = 387) (n = 129)
198 (51.2%) 59 (45.7%) 0.286 1.24 0.83–1.85
Perianal fistulas (n = 513)
45/387 (11.6%) 13/129 (10.1%) 0.611 1.184 0.62–2.27
Stenoses (n = 518)
(n = 390) (n = 128)
249 (63.9%) 77 (60.2%) 0.519 1.14 0.76–1.72
For each variable, the number of patients included is given.
1Disease behaviour was defined according to the Montreal classification. A stricturing disease phenotype was defined as presence of a stenosis without penetrating
disease. The diagnosis of stenoses was made surgically, endoscopically, or radiologically (using MR enteroclysis).
2Immunosuppressive agents included azathioprine, 6-mercaptopurine, methotrexate, infliximab, and/or adalimumab.
3Only surgery related to CD-specific problems (e.g., ileocecal resection, fistulectomy, colectomy, and ileostomy) was included.
doi:10.1371/journal.pone.0108503.t002
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an aggressive disease behavior compared to 69.3% (201/290) of
the patients with the NOD2 wild-type genotype (p = 0.007).
The presence of the minor G allele of FOXO3A
rs12212067 does not protect against a severe disease
phenotype in homozygous carriers of the NOD2
p.Leu1007fs mutation
An additional sub-analysis showed that six of the 26 patients
with the NOD2 frameshift mutation on both alleles were also
heterozygous carriers of the minor G allele of the FOXO3A SNP
rs12212067. Based on our definitions for ‘‘mild’’ and ‘‘aggressive’’
disease, five of these patients had an aggressive disease phenotype
(83.3%), while one CD patient had mild disease. This patient was
diagnosed with CD at the age of 13 years and needed
immunosuppressive treatment early on. This demonstrates, that
in carriers of the minor G allele of the FOXO3A SNP rs12212067,
no clinically protective effect on the disease course is observed if
the patients are homozygous carriers of the 1007fs NOD2 variant,
further reinforcing our conclusion that the FOXO3A rs12212067
SNP minor G allele is not associated with a mild(er) disease course
in our patient cohort. In summary, there is clinically a much
stronger effect of NOD2 1007fs homozygosity than carrier status
of the FOXOA3 rs12212067 variant, limiting the usefulness of this
FOXO3A variant in clinical practice for therapeutic decisions for
individual patients, despite its effect on the inflammatory response
of monocytes through the FOXO3-driven pathway [15].
Discussion
With the evolution of new medical therapies for the treatment of
IBD, the evaluation of an individualized treatment approach for
each IBD patient becomes more important. For defining the most
appropriate treatment algorithm in CD patients, prediction of the
subsequent disease course is indispensable for lowering the risk of
overtreatment and limiting the use of potentially harmful
immunosuppressive therapy in mild CD, and for initiating a
therapy with biologicals in early ‘‘aggressive’’ CD to lower CD-
related complications and surgery.
The present study demonstrates that the NOD2 mutant
p.Leu1007fsX1008 (rs2066847) strongly correlates with a severe
CD course. The association between the FOXO3A SNP
rs12212067 and a mild (or aggressive) disease behavior, in
contrast, was not significant in our patient cohort. However, a
post-hoc power calculation demonstrated that a very large sample
size of 4140 CD patients would be necessary to demonstrate (with
80% power) statistical significance in our study cohort if the effect
size (OR 0.83) and the allele frequency for the G allele for the
FOXO3A SNP rs12212067 (0.127) would remain stable in our
study. However, such a large cohort can only be collected in a
large multicenter study. This study is therefore not sufficient to
reject the hypothesis of an association of the FOXO3A SNP
rs12212067 with a mild disease phenotype; however, as demon-
strated by the very robust association of the NOD2 1007fs variant
with an aggressive disease phenotype (p = 2.9961025), the cohort
size is sufficient to detect clinically relevant associations. Consid-
ering the aim of our study, which tried to clarify the clinical value
of the FOXO3A SNP rs122112067 for therapeutic decisions on an
individual patient level, our data strongly suggest that - in contrast
to the strong effect of NOD2 1007fs homozygosity – the FOXO3A
SNP rs122112067 is not helpful for individual therapeutic decision
given its very low predictive value for certain CD phenotypes.
However, combining our cohort with the British CD cohort, the
association of FOXO3A SNP rs12212067 with a mild CD
phenotype remains significant (p = 1.5861028).
Our data confirmed that the NOD2 genotype status is currently
the strongest genetic marker associated with a severe CD course.
This observation is supported by several previous reports that
demonstrated the NOD2 genotype as a marker for complicated
CD [2,4,6,8,11,28,30].
Table 3. CD phenotype stratified by disease course.
Aggressive disease behaviour Mild disease behaviour
Genetic
marker
(stenosis and/or fistula and/or CD-related
surgery; n = 403)
(no stenosis, no fistula, no CD-related surgery = inflammatory
disease type; n = 147) p-value
rs12212067 G-allele (%)98/806 (12.2) 42/294 (14.3)
0.35
T-allele (%) 708/806 (87.8) 252/294 (85.7)
rs2066844 T-allele (%) 78/806 (9.7) 29/294 (9.9)
0.93
C-allele (%) 728/806 (90.3) 265/294 (90.1)
rs2066845 C-allele (%)37/806 (4.6) 10/294 (3.4)
0.39
G-allele (%) 769/806 (95.4) 284/294 (86.6)
rs2066847 X-allele (%)123/806 (15.3) 17/294 (5.8)
2.9961025
C-allele (%) 683/806 (84.7) 277/294 (94.2)
Aggressive disease behaviour was defined as stricturing and/or penetrating disease course 6 CD-related surgery. Given are the allele frequencies (upper line: minor
allele frequency in bold, bottom line: major allele frequency) for CD patients with an aggressive or with a mild disease behaviour, respectively, for the FOXOA3 SNP
rs12212067 and for the three main NOD2 mutants rs2068844, rs2066845, and rs2066847. Only the p.Leu1007fsX1008 frameshift mutation in exon 11 of the NOD2 gene
(rs2066847) was significantly associated with an aggressive disease behaviour in patients with CD (p = 2.9961025, Chi-squared test). For the two other NOD2 mutants
and especially for the FOXO3A SNP rs12212067, no significant differences were seen in the allele frequencies in patients with aggressive vs. mild disease behaviour.
Some parts of the NOD2 data have already been published elsewhere [4,28,30].
doi:10.1371/journal.pone.0108503.t003
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Table 4. CD phenotype stratified by the FOXO3A rs12212067 genotype in CD patients carrying none of the three NOD2 mutations
analyzed (NOD2 wild-type).
FOXO3A rs12212067 (1) (2) (1) vs. (2) (1) vs. (2) (1) vs. (2)
genotype status TT/NOD2 GG/TG/NOD2 p value OR 95% CI
wild-type wild-type
n = 219 n = 71
Male sex (n = 290) 94 (43%) 36 (50.7%) 0.253 0.73 0.43–1.25
Age at diagnosis (yrs, n = 280, based on median OR+CI for . median)
Mean 6 SD 28.8 6 12.1 26.4 6 10.8 0.374 1.28 0.74–2.22
Range (6–70) (4–57)
Disease duration (yrs, n = 262, based on median OR+CI for . median)
Mean 6 SD 14.569.4 16.469.4
Range (0–42) (1–40) 0.148 1.53 0.86–2.71
Body mass index (n = 223, based on median OR+CI for . median)
Mean 6 SD 23.364.0 23.263.8 0.962 0.99 0.53–1.82
Range (15.6–33.6) (16.5–31.9)
Age at diagnosis (n = 213) (n = 67)
#16 years (A1) 25 (11.7%) 8 (11.9%) 0.964 0.98 0.42–2.29
17–40 years (A2) 155 (72.8%) 52 (77.6%) 0.432 0.77 0.40–1.47
.40 years (A3) 33 (15.5%) 7 (10.5%) 0.307 1.57 0.66–3.74
Location (n = 280)
(n = 211) (n = 69)
Terminal ileum (L1) 33 (15.6%) 6 (8.7%) 0.154 1.95 0.78–4.87
Colon (L2) 28 (13.3%) 12 (17.4%) 0.397 0.73 0.35–1.52
Ileocolon (L3) 145 (68.7%) 51 (73.9%) 0.415 0.78 0.42–1.43
Upper GI (L4) 5 (2.4%) 0 (0%) 0.502 1.30 0.61–2.76
Any ileal involvement 178 (84.4%) 57 (82.6%) 0.731 1.14 0.55–2.34
(L1+L3)
Behaviour 1 (n = 269)
(n = 204) (n = 65)
Non-stricturing, Non-penetrat. (B1) 55 (27%) 21 (32.3%) 0.550 0.83 0.46–1.52
Stricturing (B2) 52 (25.5%) 14 (21.5%) 0.289 1.42 0.74–2.72
Penetrating (B3) 97 (47.5%) 30 (46.2%) 0.675 0.89 0.51–1.56
Use of immunosuppressive agents2 (n = 278)
(n = 209) (n = 69)
167 (79%) 54 (78.3%) 0.77 1.10 0.57–2.15
Surgery because of CD3 (n = 261)
(n = 196) (n = 65)
108 (55%) 37 (56.9%) 0.266 0.93 0.53–1.64
Fistulas (n = 266)
(n = 201) (n = 65)
97 (48%) 30 (46.1%) 0.768 1.09 0.62–1.91
Perianal fistulas (n = 266)
23/201 (11.4%) 6/65 (9.2%) 0.603 1.29 0.50–3.31
Stenoses (n = 268)
(n = 204) (n = 64)
126 (62.1%) 36 (56.3%) 0.432 1.26 0.71–2.22
Group (1): CD patients carrying the rs12212067 T variant in homozygous form (219 patients with the TT genotype and no further NOD2 mutant), group (2): CD patients
with the FOXO3A rs12212067 GG or TG genotype and no further NOD2 mutation.
1According to the Montreal classification, a stricturing disease phenotype was defined as the presence of a stenosis without penetrating disease. The diagnosis of
stenoses was made surgically, endoscopically, or radiologically (using MR enteroclysis).
2Immunosuppressive agents included azathioprine, 6-mercaptopurine, methotrexate, infliximab, and/or adalimumab.
3Only surgery related to CD-specific problems (e.g., ileocecal resection, fistulectomy, colectomy, and ileostomy) was included.
doi:10.1371/journal.pone.0108503.t004
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An additional explanation for the observed differences between
the German and the British cohort may be different definitions of
‘‘aggressive’’ and of ‘‘indolent’’/‘‘mild’’ CD. We used a stricter
definition of ‘‘aggressive’’ CD, as we only included CD patients
with penetrating and/or stricturing CD, with and without CD-
related surgery. Furthermore, over 80% of our patients needed
immunosuppressive therapy. Seventy-three percent of these
patients therefore had an aggressive disease compared to 63% of
patients in the cohort of Lee et al. [15]. Unfortunately, there is no
information on the NOD2 genotype status in the study of Lee et al.
Therefore, it remains unclear if the results of the British study can
be explained independently of the NOD2 genotype.
As mentioned above, one limitation of our study is the lower
number of CD patients included in the overall analysis (550 CD
patients in our study vs. a total of 2.985 CD patients in the study of
Lee et al. [15]). However, our study cohort is phenotypically
characterized in more detail than the cohorts of the British study,
providing disease phenotypes and clinical information for all
patients. Nevertheless, the FOXO3A minor allele frequencies (see
above) regarding the proportions of CD patients with ‘‘mild’’
disease behaviour were comparable between the British and our
German IBD cohort (13.1% in patients with ‘‘indolent’’ CD in the
British IBD cohort versus 14.3% in patients with ‘‘mild’’ CD in
our IBD cohort).
Although the follow-up period in our patient group with mild
disease (45.6 months) was comparable to that of patients with
severe disease (49.8 months), it cannot be excluded that patients
with mild CD convert later to a severe disease phenotype which
may take in some patients up to 20 years. However, given that the
definition of ‘‘mild disease’’ in the study by Lee et al. [15] was
defined as ‘‘disease of greater than 4 years duration, for which
immunomodulators or intestinal resections had never been
required’’ and our median follow-up in both CD subgroups was
approximately four years, we assume that major differences in
disease duration are not the main reason for the observed
differences in the German and the British study.
In conclusion, in clinical practice, the FOXO3A SNP
rs12212067 is – in contrast to the 1007fs NOD2 variant not a
relevant genetic marker for therapeutic decisions on an individual
patient level despite its impact on the inflammatory response of
monocytes [15]. Our study indicates that the clinical value of the
three NOD2 mutants for relevant therapeutic decisions is mainly
limited to the frameshift mutation p.Leu1007fs in exon 11.
Especially CD patients carrying this alteration in homozygous
form have a complicated disease course. In these patients, a ‘‘top
down’’ approach with an early initiation of anti-TNF therapy
and/or immunosuppressive therapy seems to be justified.
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